TUBA3C

Tubulin alpha-3C chain (EC 3.6.5.-) (Alpha-tu · P0DPH7 · TUBA3C on Sugi Atlas →

133,739 patent compounds predicted against TUBA3C, 84,847 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Curacin A Curacin A (SCHEMBL61304) 1.00 20/20
Vintriptol Vintriptol (SCHEMBL93959) 1.00 15/20
Vindesine Vindesine (SCHEMBL4420) 0.85 13/20
Vindesine Vindesine (SCHEMBL4421) 0.85 13/20
Vindesine Vindesine (SCHEMBL4285) 0.85 12/20
SCHEMBL147173 SCHEMBL147173 0.50 12/20
SCHEMBL147174 SCHEMBL147174 0.50 12/20
Combretastatin Combretastatin (SCHEMBL19955) 1.00 9/20
Combretastatin Combretastatin (SCHEMBL19956) 1.00 9/20
SCHEMBL118593 SCHEMBL118593 0.69 9/20
Centaureidin Centaureidin (SCHEMBL9953) 1.00 8/20
Thiocolchicine Thiocolchicine (SCHEMBL43160) 1.00 8/20
Thiocolchicine Thiocolchicine (SCHEMBL43161) 1.00 8/20
SCHEMBL68067 SCHEMBL68067 0.62 8/20
Fosbretabulin Fosbretabulin (SCHEMBL66079) 0.61 8/20
Vinorelbine Vinorelbine (SCHEMBL4765) 1.00 7/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18945) 1.00 7/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18946) 1.00 7/20
Levofloxacin Anhydrous Levofloxacin Anhydrous (SCHEMBL15397) 0.98 7/20
Ofloxacin Ofloxacin (SCHEMBL24373) 0.98 7/20

Clinical trials — most relevant to TUBA3C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer PHASE3COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
IVM Alone vs ALB + IVM Against Onchocerciasis PHASE3COMPLETED
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients. PHASE3COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer PHASE2COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer PHASE2UNKNOWN
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) PHASE2COMPLETED
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer PHASE1/PHASE2NOT_YET_RECRUITING
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Exploratory Evaluation of [11C]MPC6827 EARLY_PHASE1COMPLETED
Diagnostic of Chemotherapy Induced Neuropathy in Children nanCOMPLETED
Importance of the Microtubule Cytoskeleton in Oocyte Competence nanCOMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
Effect of Low Dose of Colchicine on Platelet Reactivity nanCOMPLETED
Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods nanUNKNOWN
Diagnosis of Primary Ciliary Dyskinesia nanCOMPLETED
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
WGS of Korean Idiopathic Bronchiectasis nanUNKNOWN
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients nanCOMPLETED
Mapping Disease Pathways for Biliary Atresia nanRECRUITING
Autophagy Bladder Cancer nanUNKNOWN
PCD New Gene Discovery nanCOMPLETED
Early Detection and Characterization of Primary Ciliary Dyskinesia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TUBA3C binder may also engage these)

ProteinNameSimilarity
P02552 1.000 P02552 →
P68369 1.000 P68369 →
P0DPH8 1.000 P0DPH8 →
TUBA4A Tubulin alpha-4A chain 1.000 landscape →
Q32KN8 1.000 Q32KN8 →
Q68FR8 1.000 Q68FR8 →
A5A6J1 1.000 A5A6J1 →
P05214 1.000 P05214 →
Q91060 1.000 Q91060 →
Q52PV9 1.000 Q52PV9 →
P18288 1.000 P18288 →
Q94572 1.000 Q94572 →
P06604 1.000 P06604 →
P68360 1.000 P68360 →
Q2HJB8 1.000 Q2HJB8 →
P68370 1.000 P68370 →
Q6AYZ1 1.000 Q6AYZ1 →
P02550 1.000 P02550 →
Q2HJ86 1.000 Q2HJ86 →
Q06331 1.000 Q06331 →
TUBA3E Tubulin alpha-3E chain (EC 3.6.5.-) (Alpha-tu 1.000 landscape →
P68373 1.000 P68373 →
Q8T6A5 1.000 Q8T6A5 →
Q25008 1.000 Q25008 →
P34690 1.000 P34690 →
Q6AY56 1.000 Q6AY56 →
P68361 1.000 P68361 →
P68368 1.000 P68368 →
P28287 1.000 P28287 →
P68367 1.000 P68367 →